

James B Whitney

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8940023/publications.pdf>

Version: 2024-02-01

39
papers

2,335
citations

430874

18
h-index

289244

40
g-index

43
all docs

43
docs citations

43
times ranked

3941
citing authors

#	ARTICLE	IF	CITATIONS
1	Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. <i>Nature</i> , 2014, 512, 74-77.	27.8	527
2	Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. <i>Science</i> , 2015, 349, 320-324.	12.6	303
3	Zika viral dynamics and shedding in rhesus and cynomolgus macaques. <i>Nature Medicine</i> , 2016, 22, 1448-1455.	30.7	270
4	Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. <i>Science Translational Medicine</i> , 2011, 3, 81ra36.	12.4	179
5	A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes. <i>PLoS Pathogens</i> , 2016, 12, e1005545.	4.7	142
6	TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	133
7	Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	106
8	Zika plasma viral dynamics in nonhuman primates provides insights into early infection and antiviral strategies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 8847-8852.	7.1	89
9	The human IL-15 superagonist ALT-803 directs SIV-specific CD8+ T cells into B-cell follicles. <i>Blood Advances</i> , 2018, 2, 76-84.	5.2	78
10	Nonhuman Primate Models of Zika Virus Infection, Immunity, and Therapeutic Development. <i>Journal of Infectious Diseases</i> , 2017, 216, S928-S934.	4.0	49
11	Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy. <i>Nature Communications</i> , 2018, 9, 5429.	12.8	49
12	Evidence that CD32a does not mark the HIV-1 latent reservoir. <i>Nature</i> , 2018, 561, E20-E28.	27.8	43
13	Serpin Induced Antiviral Activity of Prostaglandin Synthetase-2 against HIV-1 Replication. <i>PLoS ONE</i> , 2011, 6, e18589.	2.5	37
14	Leader Sequences Downstream of the Primer Binding Site Are Important for Efficient Replication of Simian Immunodeficiency Virus. <i>Journal of Virology</i> , 2000, 74, 8854-8860.	3.4	28
15	Generation and Evaluation of Clade C Simian-Human Immunodeficiency Virus Challenge Stocks. <i>Journal of Virology</i> , 2015, 89, 1965-1974.	3.4	28
16	A direct-acting antiviral drug abrogates viremia in Zika virus-infected rhesus macaques. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	21
17	In Vitro and In Vivo Models of HIV Latency. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1075, 241-263.	1.6	19
18	Novel, Live Attenuated Simian Immunodeficiency Virus Constructs Containing Major Deletions in Leader RNA Sequences. <i>Journal of Virology</i> , 2001, 75, 2776-2785.	3.4	18

#	ARTICLE	IF	CITATIONS
19	Genital Tract Sequestration of SIV following Acute Infection. <i>PLoS Pathogens</i> , 2011, 7, e1001293.	4.7	18
20	Natural and cross-inducible anti-SIV antibodies in Mauritian cynomolgus macaques. <i>PLoS ONE</i> , 2017, 12, e0186079.	2.5	18
21	Production of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env Sequences. <i>PLoS Pathogens</i> , 2016, 12, e1005431.	4.7	18
22	Impaired RNA incorporation and dimerization in live attenuated leader-variants of SIVmac239. <i>Retrovirology</i> , 2006, 3, 96.	2.0	14
23	T-Cell Vaccination Reduces Simian Immunodeficiency Virus Levels in Semen. <i>Journal of Virology</i> , 2009, 83, 10840-10843.	3.4	14
24	Monitoring HIV vaccine trial participants for primary infection: studies in the SIV/macaque model. <i>Aids</i> , 2009, 23, 1453-1460.	2.2	13
25	Galidesivir, a Direct-Acting Antiviral Drug, Abrogates Viremia in Rhesus Macaques Challenged with Zika Virus. <i>Open Forum Infectious Diseases</i> , 2017, 4, S55-S55.	0.9	13
26	The M184V Mutation in Reverse Transcriptase Can Delay Reversion of Attenuated Variants of Simian Immunodeficiency Virus. <i>Journal of Virology</i> , 2002, 76, 8958-8962.	3.4	12
27	Prior exposure to an attenuated <i>Listeria</i> vaccine does not reduce immunogenicity: pre-clinical assessment of the efficacy of a <i>Listeria</i> vaccine in the induction of immune responses against HIV. <i>Journal of Immune Based Therapies and Vaccines</i> , 2011, 9, 2.	2.4	12
28	Mucosal antibody responses to vaccines targeting SIV protease cleavage sites or full-length Gag and Env proteins in Mauritian cynomolgus macaques. <i>PLoS ONE</i> , 2018, 13, e0202997.	2.5	11
29	Microbial Dysbiosis During Simian Immunodeficiency Virus Infection is Partially Reverted with Combination Anti-retroviral Therapy. <i>Scientific Reports</i> , 2020, 10, 6387.	3.3	11
30	Mauritian cynomolgus macaques with M3M4 MHC genotype control SIVmac251 infection. <i>Journal of Medical Primatology</i> , 2017, 46, 137-143.	0.6	10
31	Zika virus research models. <i>Virus Research</i> , 2018, 254, 15-20.	2.2	9
32	Vaccine targeting SIVmac251 protease cleavage sites protects macaques against vaginal infection. <i>Journal of Clinical Investigation</i> , 2020, 130, 6429-6442.	8.2	7
33	Evolutionary mechanisms of retroviral persistence. <i>AIDS Reviews</i> , 2011, 13, 234-9.	1.0	7
34	Partial Restoration of Replication of Simian Immunodeficiency Virus by Point Mutations in either the Dimerization Initiation Site (DIS) or Gag Region after Deletion Mutagenesis within the DIS. <i>Journal of Virology</i> , 2001, 75, 11920-11923.	3.4	5
35	BCX4430, a Broad-Spectrum Adenosine Analog Direct-Acting Antiviral Drug, Abrogates Viremia in Rhesus Macaques Challenged With Zika Virus. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	5
36	Recovery of fitness of a live attenuated simian immunodeficiency virus through compensation in both the coding and non-coding regions of the viral genome. <i>Retrovirology</i> , 2007, 4, 44.	2.0	3

#	ARTICLE	IF	CITATIONS
37	Models of SIV rebound after treatment interruption that involve multiple reactivation events. PLoS Computational Biology, 2020, 16, e1008241.	3.2	3
38	Cervico-Vaginal Inflammatory Cytokine and Chemokine Responses to Two Different SIV Immunogens. Frontiers in Immunology, 2020, 11, 1935.	4.8	3
39	Tâ€œcell subset differentiation and antibody responses following antiretroviral therapy during simian immunodeficiency virus infection. Immunology, 2018, 155, 458-466.	4.4	1